Neurogene - Developing Purpose-built Genetic Medicines
Neurogene is a clinical-stage gene therapy company advancing genetic medicines for rare neurological diseases, with its lead program NGN-401 targeting Rett syndrome using a proprietary EXACT technology platform designed to overcome dosage-sensitivity limitations of conventional gene therapy approaches.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountNov 2024
Dec 2023
Dec 2020
Feb 2019
Create a free account to see which investors have funded this company.
Create Free Account
BridgeBio Pharma is a clinical-stage biopharmaceutical company developing therapies for genetic d...
Clinical-stage biopharmaceutical company developing FcRn inhibitor therapies for IgG-mediated aut...
Commercial-stage oncology company pioneering antibody drug conjugate therapies for cancer treatment.
Global clinical-stage biopharmaceutical company pursuing novel drug development platforms for rar...
Research-based development stage biopharmaceutical company that discovers and develops innovative...
Clinical-stage biopharmaceutical company developing T cell receptor-based adoptive cell therapies...
